Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HK1 | P19367 | 1/20 | 0.42 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9579908 | 0.89 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CPLAUL3MBTL1 | |
| SCHEMBL503314 | 0.79 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CPLAUL3MBTL1 | |
| SCHEMBL5801527 | 0.75 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CPLAUGABRA1 | |
| SCHEMBL7913558 | 0.75 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CPLAUL3MBTL1 | |
| SCHEMBL558038 | 0.74 | GABRP (0.40) | ADRA2AADRA2BADRA2CPLAUGABRA1 | |
| SCHEMBL1880838 | 0.72 | GABRP (0.37) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| SCHEMBL1826488 | 0.72 | ALDH1A1 (0.40) | L3MBTL1GABRA1GABRB2GABRPGABRD | |
| SCHEMBL29696296 | 0.72 | APLNR (0.42) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| SCHEMBL1868513 | 0.72 | APLNR (0.42) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| SCHEMBL6730549 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103694243-B | 2-substituted pyridinyl-1,2,4-triazolo [1,2-a] pyridazine compound | CHINA AGRICULTURAL UNIVERSITY (CN) | 2015-09-09 | — | — | CN | disclosed |
| CN-103694243-A | 2-substituted pyridyl-1,2,4-triazol [1,2-a] pyridazine compound | UNIV CHINA AGRICULTURAL | 2014-04-02 | — | — | CN | disclosed |
| US-20040116418-A1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 2004-06-17 | — | — | US | disclosed |
| EP-0540143-B1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 2003-02-05 | — | — | EP | disclosed |
| US-20020132794-A1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB | 2002-09-19 | — | — | US | disclosed |
| US-6376492-B1 | GUANIDINE DERIVATIVES | MEDIVIR AB (SE) | 2002-04-23 | — | — | US | disclosed |
| US-5849769-A | N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection | MEDIVIR AB (SE) | 1998-12-15 | — | — | US | disclosed |
| EP-0706514-B1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1998-11-18 | — | — | EP | disclosed |
| US-5714503-A | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 1998-02-03 | — | — | US | disclosed |
| US-5658907-A | THIOUREA VIRICIDES | MEDIVIR A/B (SE) | 1997-08-19 | — | — | US | disclosed |
| US-5593993-A | VIRICIDES FOR HTLV TREATMENT OF AIDS | MEDIVIR AB (SE) | 1997-01-14 | — | — | US | disclosed |
| EP-0706514-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995006034-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1995-03-02 | — | — | WO | disclosed |
| EP-0540143-A2 | Compounds and methods for inhibition of HIV and related viruses | Medivir Aktiebolag (SE) | 1993-05-05 | — | — | EP | disclosed |
| US-4565826-A | HYPOTENSIVE, CARDIONASCULAR, ANTIULCER, ANTISECRETORY, GASTROINTESTINAL DISORDERS | WILLIAM H. RORER, INC. (US) | 1986-01-21 | — | — | US | disclosed |
| EP-0078839-A4 | HETEROCYCLIC AMIDINOUREAS. | RORER INTERNAT OVERSEAS INC (US) | 1984-07-25 | — | — | EP | disclosed |
| US-4436911-A | HYPOTENSIVE, ANTISPASMODIC, ANTIULCER, ANTIPARASITIC | WILLIAM H. RORER, INC. (US) | 1984-03-13 | — | — | US | disclosed |
| EP-0078839-A1 | HETEROCYCLIC AMIDINOUREAS | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1983-05-18 | — | — | EP | disclosed |
| WO-1982004047-A1 | HETEROCYCLIC AMIDINOUREAS | RORER INT OVERSEAS (US) | 1982-11-25 | — | — | WO | disclosed |
| US-3984549-A | FUNGICIDES | MERCK & CO., INC. (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132794-A1 | Compounds and methods for inhibition of HIV and related viruses | POLRMT, POLM, POLR1E | ADRA2A 4837/4885ADRA2B 4756/4885ADRA2C 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.